We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
Read MoreHide Full Article
Key Takeaways
Amarin posted adjusted Q3 earnings of 1 cent per share, missing the estimated 8 cents.
Quarterly revenues rose 17% year over year to $49.7 million, topping expectations.
U.S. Vascepa sales surged 34%, offsetting weaker European and rest-of-world revenues.
Amarin Corporation (AMRN - Free Report) reported adjusted earnings of 1 cent per share for the third quarter of 2025, which missed the Zacks Consensus Estimate of 8 cents per share. The company had reported an adjusted loss of 5 cents per share in the year-ago quarter.
The reported earnings excluded stock-based compensation expense and restructuring expense. Including these, the company incurred a loss of 2 cents per share in the third quarter of 2025 compared with a loss of 6 cents per share reported in the year-ago quarter.
Total revenues in the third quarter were $49.7 million, which beat the Zacks Consensus Estimate of $43 million. The top line increased 17% from the year-ago quarter’s level, owing to higher product sales in the United States.
Shares of Amarin were down 11.3% on Oct. 29 following the announcement of the results.
The stock has rallied 73.3% so far this year compared with the industry’s increase of 10.8%.
Image Source: Zacks Investment Research
AMRN's Q3 Earnings in Detail
Net product revenues from Vascepa, the company’s sole marketed drug, in the third quarter were $48.6 million, representing a 16% year-over-year increase.
U.S. product revenues from Vascepa totaled $40.9 million, surging 34% from the year-ago quarter’s level owing to a higher net selling price and an increase in volume driven by regaining exclusive status with a large pharmacy benefit manager. The drug’s U.S. sales beat our model estimate of $24.7 million.
Product revenues from Vazkepa (Vascepa’s brand name in Europe) in the European market totaled $4.1 million, decreasing 5% from the year-ago quarter. This was due to the company’s initial transition to a fully partnered model with Recordati in the European market.
Revenues in the rest of the world were $3.6 million, down 48% year over year.
Licensing and royalty revenues came in at $1.1 million in the third quarter, increasing 149% on a year-over-year basis. The increase was driven by increased royalty revenues from in-market sales generated by AMRN’s partners.
Selling, general and administrative expenses declined 47% year over year to $19.7 million, reflecting the impact of the recent restructuring process and cost optimization efforts.
Research and development expenses totaled $4.2 million, down 7% year over year.
Amarin ended the third quarter with cash and investments of $286.6 million compared with $298.7 million as of June 30, 2025.
Along with the Recordati licensing deal, the company initiated a global restructuring, which is expected to deliver approximately $70 million in cost savings over the next year.
Per management, the partnership with Recordati is expected to accelerate growth for Vazkepa across the European market. Per management, the European transition with Recordati has been progressing well as the company expects to achieve positive free cash flow in 2026.
Amarin Corporation PLC Price, Consensus and EPS Surprise
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 66.8%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.36 to $4.23 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.41 to $4.21. Year to date, shares of BEAM have lost 0.1%.
Beam Therapeutics’ earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average negative surprise being 2.62%.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from $1.22 to $1.85 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.12 to $2.49. Year to date, shares of CRMD have rallied 39.6%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, the average surprise being 34.85%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
Key Takeaways
Amarin Corporation (AMRN - Free Report) reported adjusted earnings of 1 cent per share for the third quarter of 2025, which missed the Zacks Consensus Estimate of 8 cents per share. The company had reported an adjusted loss of 5 cents per share in the year-ago quarter.
The reported earnings excluded stock-based compensation expense and restructuring expense. Including these, the company incurred a loss of 2 cents per share in the third quarter of 2025 compared with a loss of 6 cents per share reported in the year-ago quarter.
Total revenues in the third quarter were $49.7 million, which beat the Zacks Consensus Estimate of $43 million. The top line increased 17% from the year-ago quarter’s level, owing to higher product sales in the United States.
Shares of Amarin were down 11.3% on Oct. 29 following the announcement of the results.
The stock has rallied 73.3% so far this year compared with the industry’s increase of 10.8%.
Image Source: Zacks Investment Research
AMRN's Q3 Earnings in Detail
Net product revenues from Vascepa, the company’s sole marketed drug, in the third quarter were $48.6 million, representing a 16% year-over-year increase.
U.S. product revenues from Vascepa totaled $40.9 million, surging 34% from the year-ago quarter’s level owing to a higher net selling price and an increase in volume driven by regaining exclusive status with a large pharmacy benefit manager. The drug’s U.S. sales beat our model estimate of $24.7 million.
Product revenues from Vazkepa (Vascepa’s brand name in Europe) in the European market totaled $4.1 million, decreasing 5% from the year-ago quarter. This was due to the company’s initial transition to a fully partnered model with Recordati in the European market.
Revenues in the rest of the world were $3.6 million, down 48% year over year.
Licensing and royalty revenues came in at $1.1 million in the third quarter, increasing 149% on a year-over-year basis. The increase was driven by increased royalty revenues from in-market sales generated by AMRN’s partners.
Selling, general and administrative expenses declined 47% year over year to $19.7 million, reflecting the impact of the recent restructuring process and cost optimization efforts.
Research and development expenses totaled $4.2 million, down 7% year over year.
Amarin ended the third quarter with cash and investments of $286.6 million compared with $298.7 million as of June 30, 2025.
AMRN's Recent Key Developments
Amarin signed an exclusive long-term license and supply agreement with Italy-based pharma company, Recordati, to commercialize Vazkepa across 59 countries in the European Union in June.
Along with the Recordati licensing deal, the company initiated a global restructuring, which is expected to deliver approximately $70 million in cost savings over the next year.
Per management, the partnership with Recordati is expected to accelerate growth for Vazkepa across the European market. Per management, the European transition with Recordati has been progressing well as the company expects to achieve positive free cash flow in 2026.
Amarin Corporation PLC Price, Consensus and EPS Surprise
Amarin Corporation PLC price-consensus-eps-surprise-chart | Amarin Corporation PLC Quote
AMRN's Zacks Rank & Stocks to Consider
Amarin currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) , Beam Therapeutics (BEAM - Free Report) and CorMedix (CRMD - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 66.8%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.36 to $4.23 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.41 to $4.21. Year to date, shares of BEAM have lost 0.1%.
Beam Therapeutics’ earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average negative surprise being 2.62%.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from $1.22 to $1.85 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.12 to $2.49. Year to date, shares of CRMD have rallied 39.6%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, the average surprise being 34.85%.